Antidepressant combinations: Cutting edge psychopharmacology or passing fad? Topical collection on mood disorders

Current Psychiatry Reports

Volumn 15, Issue 10, 2013, Pages

  Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressants; Bupropion; Mirtazapine; MOI; Monoamine oxidase inhibitor; Mood disorders; Psychiatry; Psychopharmacology; Selective serotonin reuptake inhibitor; Serotonin norepinephrine reuptake inhibitor; SNRI; SSRI; TCA; Tricyclic antidepressant

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

DRUG COMBINATION; HUMAN; MAJOR DEPRESSION; METHODOLOGY; REVIEW; DEPRESSIVE DISORDER, MAJOR; PROCEDURES;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84885120355     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0403-2     Document Type: Article

References (24)

1. • Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26-36. This article provides evidence about temporal changes in treatment selection and documents the prevalence of combining antidepressants.
2. • Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;30:1-10. A good summary of the rationale for combining antidepressants and the pros and cons of monotherapy versus combination therapy.
3. Rush AJ. Combining antidepressant medications: a good idea? Am J Psychiatry. 2010;167(3):241-3.
4. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97-105. (Pubitemid 46588311)
5. Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry. 2011;56(6):317-23.
6. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34(3):187-92.
7. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185-219.
8. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7 Suppl 1:11-7.
9. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry. 2002;63(8):685-93.
10. Nelson JC, Mazure CM, Bowers Jr MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-7.
11. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151(9):1372-4. (Pubitemid 24281764)
12. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22(4):379-87. (Pubitemid 34810327)
13. Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300. (Pubitemid 38117167)
14. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002;163(1):102-5. (Pubitemid 34985318)
15. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54(8):800-5. (Pubitemid 37205131)
16. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65(3):337-40.
17. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
18. •• Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701. A very important randomized trial evaluating whether antidepressant combinations might accelerate remission or improve outcomes if used from the outset of therapy. This large multicenter study found no evidence to support the use of combined therapy from the outset of treatment.
19. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR D trial. Acta Psychiatr Scand. 2012;125(4):342-8.
20. Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189-98.
21. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-8. (Pubitemid 34127908)
22. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19:457-65.
23. •• Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-8. In contrast to the findings of COMED, this single center study found that vigorously dosed combinations were more effective than monotherapy with fluoxetine.
24. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR D report. Am J Psychiatry. 2006;163(9):1531-41. (Pubitemid 44465752)